That’s not necessarily a negative, as it will mean plenty of incentive for the company to be run prudently because Johnson & Johnson will still have a lot of skin in the game. That means less risk-taking and perhaps more conservatism, which caters to the preferences of dividend investors rather than to those looking for an aggressive growth stock. We’ve always believed in the power of new perspectives and insights to drive innovation.
Johnson’s Baby
Johnson & Johnson (JNJ -0.21%) officially spun off its consumer health business this month, creating the largest U.S. initial public offering since 2021. Kenvue (KVUE -0.04%) began trading as a stand-alone business and gives healthcare investors a new stock to potentially add to their portfolios. It now controls the production and sale of top products like Band-Aid, Tylenol, and Neutrogena, and it will offer a dividend, just as its parent company does. If you’ve heard of Kenvue, you may already know that we’re a global consumer health company.
Is Kenvue Stock a Buy Now?
You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. We’re driven to win for those we this gamestop stock fiasco is getting out of hand serve, and when we care fiercely for them and one another, we can deliver the best possible care. Together, we create an inclusive place where we can bring our whole selves.
- Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.
- The year-over-year change in both measures reflects the impact of the year-over-year increase in brand investment, which more than offset the benefit from Gross profit margin expansion and savings from Our Vue Forward.
- Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning.
- Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.
- Short interest is the number of shares that have been sold short but have not yet been covered or closed out.
Why I wouldn’t rush out to buy Kenvue stock
A number of other hedge funds and other institutional investors have also bought and sold shares of KVUE. Leo Wealth LLC boosted its position in Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns a complete currency trader video review 151,611 shares of the company’s stock valued at $3,507,000 after purchasing an additional 481 shares during the last quarter. FSB ADV boosted its holdings in shares of Kenvue by 6.2% in the 3rd quarter. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after buying an additional 492 shares during the last quarter. Wolff Wiese Magana LLC boosted its holdings in shares of Kenvue by 0.7% in the 3rd quarter.
We’ve always prioritized science as the core of how we provide care, and this will never change. Value realization was driven by a combination of carry-over pricing and price actions taken this year. The volume decline was driven primarily by Skin Health and Beauty and Self Care, partially offset by growth in Essential Health.
The new logo centers on the “K” symbol, embodying the company’s strengths – the geometry of the rectangle representing scientific precision and the round edges evoking the warmth of care. The corporate name is depicted in a distinctive logotype in a rich green. This strong, distinctive color works in harmony with the multicolored vantagefx forex broker review palette of the company’s portfolio of well-known brands. In May 2023, Kenvue made our debut as a public company on the New York Stock Exchange, trading under the KVUE ticker symbol.
Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Shares of Kenvue are largely unchanged so far this year, while the S&P has risen about 23%.
